消癌平注射液联合TP方案治疗晚期非小细胞肺癌痰湿瘀阻证的疗效观察

刘殿龙; 李经蕾; 邸明一; 张伟; 侯炜

doi:10.16766/j.cnki.issn.1674-4152.002890

消癌平注射液联合TP方案治疗晚期非小细胞肺癌痰湿瘀阻证的疗效观察

doi: 10.16766/j.cnki.issn.1674-4152.002890

刘殿龙^{1, 2},
李经蕾^{1, 2},
邸明一³,
张伟⁴,
侯炜^2, ,

1.
北京中医药大学中医学院，北京 100029
2.
中国中医科学院广安门医院肿瘤科，北京 100053
3.
北京协和医院肺病科，北京 100730
4.
北京大学肿瘤医院中西结合肿瘤科，北京 100142

基金项目:

北京市科学技术委员会计划资助项目 D161100005116001

国家中医临床研究基地业务建设科研专项课题资助项目 2015ZSB01

详细信息

通讯作者:
侯炜, E-mail: houwei1964@163.com

中图分类号: R734.2 R730.58
计量
- 文章访问数: 111
- HTML全文浏览量: 84
- PDF下载量: 8
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-01
- 网络出版日期: 2023-04-19

Clinical observation of Xiaoaiping Injection combined with TP regimen in the treatment of advanced non-small cell lung cancer with phlegm-damp-stasis syndrome

LIU Dianlong^{1, 2},
LI Jinglei^{1, 2},
DI Mingyi³,
ZHANG Wei⁴,
HOU Wei^{2
, ,}

1.
College of Traditional Chinese Medicine, Beijing University of Traditional Chinese Medicine, Beijing 100029, China

摘要

摘要: 目的观察比较消癌平注射液联合TP化疗及单纯化疗两种治疗方式对ⅢB~ Ⅳ期非小细胞肺癌患者的临床疗效。方法采用前瞻性队列研究方法, 纳入ⅢB~Ⅳ期非小细胞肺癌痰湿瘀阻证患者，治疗组及对照组各53例。对照组给予TP化疗, 治疗组为TP方案联合消癌平注射液治疗。比较2组治疗2个疗程后的客观有效率(RR)和疾病控制率(DCR)、中医证候量表积分、欧洲生活质量协作组癌症核心(QLQ-C30)量表积分。比较治疗前后肿瘤标记物、凝血指标及炎症因子水平，并评估治疗过程中不良事件的发生情况。结果 2个疗程后治疗组RR为41.5%(22/53)，DCR为71.7%(38/53)，对照组分别为35.8%(19/53)和62.3%(33/53)。治疗组患者中医证候量表积分低于对照组(P＜0.05)，QLQ-C30量表疲乏和总体健康状况改善明显(均P＜0.05)。治疗组肿瘤标记物CEA、细胞角蛋白19片段低于对照组(均P＜0.05)；治疗组活化部分凝血活酶时间高于对照组、D-二聚体低于对照组(均P＜0.05)；治疗组炎症因子PCT低于对照组(P＜0.05)。治疗组不良事件中血小板降低发生率低于对照组(P＜0.05)。结论消癌平注射液联合TP方案在改善中医临床症状、提高生命质量方面有优势，能预防血小板下降的发生，综合提高晚期非小细胞肺癌痰湿瘀阻证的疗效。
- 非小细胞肺癌 /
- 联合治疗 /
- 消癌平注射液 /
- 痰湿瘀阻证
Abstract: Objective This study aims to observe and compare the clinical efficacy of Xiaoaiping Injection combined with TP chemotherapy and chemotherapy alone in patients with non-small cell lung cancer with phlegm dampness stasis syndrome. Methods A prospective cohort study was used to enroll patients with stage ⅢB-Ⅳ non-small cell lung cancer with phlegm dampness stasis syndrome, There were 53 cases in the treatment group and 53 cases in the control group. The control group was treated with TP chemotherapy, while the treatment group was treated with TP regimen combined with Xiaoaiping Injection. The objective response rate (RR), disease control rate (DCR), TCM syndrome scale score, and the European Quality of Life Collaboration Cancer Core (QLQ-C30) scale score were evaluated and compared between the 2 groups after 2 courses of treatment. The levels of tumor markers, coagulation indicators and inflammatory factors before and after treatment were compared, and the adverse events during treatment were evaluated. Results The objective RR and DCR in the treatment group were 41.5% (22/53) and 71.7% (38/53), after 2 courses of treatment, while those in the control group were 35.8% (19/53) and 62.3% (33/53) respectively. The integral of TCM syndrome scale in the treatment group were lower than those in the control group (P < 0.05), and the QLQ-C30 scale had significant advantages in fatigue improvement and overall health sub items (both P < 0.05). The tumor markers CEA and cytokeratin 19 fragment in the treatment group were lower than those in the control group (all P < 0.05). The activated partial thromboplastin time in the treatment group was higher than that in the control group, and D-dimer was lower than that in the control group (all P < 0.05). The inflammatory factor PCT in the treatment group was lower than that in the control group (P < 0.05). The incidence of thrombocytopenia amongst adverse events in the treatment group was lower than that in the control group (P < 0.05). Conclusion Xiaoaiping Injection combined with TP regimen has advantages in improving TCM clinical symptoms and quality of life. It can prevent the occurrence of thrombocytopenia, and comprehensively improve the treatment effect of advanced non-small cell lung cancer with phlegm damp blood stasis syndrome.
- Non small cell lung cancer /
- Combined therapy /
- Xiaoaiping Injection /
- Syndrome of phlegm dampness and blood stasis

HTML全文

表 1 2组非小细胞肺癌患者人口学及临床基线资料比较

Table 1. Comparison of demographic and clinical baseline data between the two groups of patients with non-small cell lung cancer

项目	对照组(53例)	治疗组(53例)	统计量	P值
性别(例)			0.854^a	0.356
男性	39	43
女性	14	10
入组年龄(x±s，岁)	60.07±5.84	63.73±5.43	-1.964^b	0.052
吸烟史(例)			1.420^a	0.233
吸烟	24	18
不吸烟	29	35
病理类型(例)			0.155^a	0.693
腺癌	32	30
鳞状细胞癌	21	23
肿瘤部位(例)			0.606^a	0.436
中央型	23	27
周围型	30	26
临床分期(例)			0.052^a	0.819
ⅢB	13	12
Ⅳ	40	41
注：^a为χ²值，^b为t值。

下载: 导出CSV

表 2 2组非小细胞肺癌患者治疗2个周期后疗效比较[例(%)]

Table 2. Comparison of efficacy between the two groups of patients with non-small cell lung cancer after 2 cycles of treatment [cases (%)]

组别	例数	CR	PR	SD	PD	RR	DCR
治疗组	53	3(5.7)	19(35.8)	16(30.2)	15(28.3)	22(41.5)	38(71.7)
对照组	53	1(1.8)	18(34.0)	14(26.4)	20(37.7)	19(35.8)	33(62.3)
χ²值						0.358	1.066
P值						0.550	0.302

下载: 导出CSV

表 3 2组非小细胞肺癌患者治疗2个周期后中医临床症状积分比较[M(P₂₅, P₇₅)，分]

Table 3. Comparison of TCM clinical symptom scores between the two groups of patients with non-small cell lung cancer after 2 cycles of treatment[M(P₂₅, P₇₅), points]

组别	例数	治疗前	治疗后	Z值	P值
治疗组	53	6(4, 7)	4(2, 5)	-0.889	0.374
对照组	53	6(4, 7)	5(4, 6)	-3.427	0.001
Z值		-0.408	-2.648
P值		0.683	0.003

下载: 导出CSV

表 4 2组非小细胞肺癌患者治疗2个周期后QLQ-C30量表积分差值比较[M(P₂₅, P₇₅)，分]

Table 4. Comparison of QLQ-C30 scale score differences between the two groups of patients with non-small cell lung cancer after 2 cycles of treatment[M(P₂₅, P₇₅), points]

子项	对照组(53例)	治疗组(53例)	Z值	P值
躯体功能	0(0, 1)	1(0, 2)	-1.889	0.059
角色功能	0(0, 0)	0(0, 0)	-1.025	0.305
认知功能	0(0, 0)	1(0, 1)	-1.658	0.097
情绪功能	0(0, 1)	0(0, 1)	-1.005	0.315
社会功能	0(0, 1)	0(0, 0)	-1.546	0.122
疲乏	1(0, 1)	1(0, 2)	-2.280	0.023
疼痛	0(0, 1)	0(0, 0)	-1.375	0.169
恶心、呕吐	1(0, 1)	0(0, 1)	-0.337	0.736
呼吸困难	0(0, 0)	0(0, 0)	-1.393	0.163
失眠	0(0, 0)	0(0, 0)	-0.109	0.913
食欲不振	0(0, 0)	0(0, 0)	-0.918	0.359
便秘	0(0, 0)	0(0, 0)	-1.297	0.195
腹泻	0(0, 0)	0(0, 0)	-0.228	0.820
经济困难	0(0, 0)	0(0, 0)	-0.186	0.852
总体健康状况	0(0, 1)	1(0, 2)	-2.213	0.027

下载: 导出CSV

表 5 2组非小细胞肺癌患者治疗前后CEA、SCC、CYFRA21-1比较(ρ/μg·L^-1)

Table 5. Comparison of CEA, SCC and CYFRA21-1 before and after treatment in the two groups of patients with non-small cell lung cancer(ρ/μg·L^-1)

组别	例数	CEA[M(P₂₅, P₇₅)]		SCC(x±s)		CYFRA21-1(x±s)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	53	46.75(26.53, 55.43)	31.89(21.97, 35.50)^b	8.61±1.95	6.06±1.67^b	9.41±3.47	7.97±3.53^b
治疗组	53	43.59(23.34, 52.13)	22.16(5.43, 15.43)^b	8.28±2.05	5.51±1.45^b	9.68±3.40	6.63±1.70^b
统计量		-1.125^a	-7.977^a	0.847^c	1.823^c	0.439^c	2.488^c
P值		0.261	＜0.001	0.399	0.071	0.509	0.015
注：^a为Z值，^c为t值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 6 2组非小细胞肺癌患者治疗前后APTT、PT、D-二聚体比较(x±s)

Table 6. Comparison of APTT, PT and D-dimer before and after treatment in patients with non-small cell lung cancer in the two groups(x±s)

组别	例数	APTT(s)		PT(s)		D-二聚体(μg/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
对照组	53	29.01±2.67	33.76±3.51^a	10.84±0.86	11.94±0.55^a	518.1±113.5	404.5±119.5^a
治疗组	53	29.66±2.84	34.91±2.29^a	10.77±0.84	12.04±0.99^a	517.0±103.1	335.0±91.8^a
t值		1.203	2.002	0.408	0.803	0.052	3.328
P值		0.232	0.048	0.684	0.424	0.959	0.001
注：与同组治疗前比较，^aP＜0.001。

下载: 导出CSV

表 7 2组非小细胞肺癌患者治疗前后CRP、PCT比较

Table 7. Comparison of CRP and PCT before and after treatment in the two groups of patients with non-small cell lung cancer

组别	例数	CRP[M(P₂₅, P₇₅)，mg/L]		PCT(x±s, μg/L)
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	53	3.06(1.09, 4.60)	1.56(0.09, 2.54)^b	3.34±0.52	2.85±0.53^b
治疗组	53	3.29(2.02, 4.04)	1.24(0.07, 1.87)^b	3.33±0.57	2.53±0.69^b
统计量		-1.365^a	-0.552^a	0.071^c	2.651^c
P值		0.172	0.581	0.944	0.009
注：^a为Z值，^c为t值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 8 2组非小细胞肺癌患者不良事件发生情况比较(例)

Table 8. Comparison of adverse events between the two groups of patients with non-small cell lung cancer (cases)

组别	例数	谷氨酰转肽酶升高	消化道不良反应	肺栓塞	骨髓抑制	血小板减少	贫血	消瘦	心律失常	血压不稳
对照组	53	14	15	0	8	14	8	12	19	7
治疗组	53	8	11	0	6	5	3	9	14	5
χ²值		2.065	0.815		0.329	5.194	2.536	0.534	1.100	0.376
P值		0.151	0.367		0.566	0.023	0.111	0.465	0.294	0.540

下载: 导出CSV

参考文献(24)

[1]	赵论, 张浩然, 石默晗, 等. 安罗替尼联合多西他赛二线治疗无驱动基因晚期非小细胞肺癌的临床疗效观察[J]. 中华全科医学, 2020, 18(4): 537-541. doi: 10.16766/j.cnki.issn.1674-4152.001292 ZHAO L, ZHANG H R, SHI M H, et al. Clinical observation of second-line treatment of anlotinib combined with docetaxel on advanced non-small cell lung cancer without driver gene mutation[J]. Chinese Journal of General Practice, 2020, 18(4): 537-541. doi: 10.16766/j.cnki.issn.1674-4152.001292
[2]	于欣欣. 多西他赛单药治疗老年晚期非小细胞肺癌的应用效果研究[J]. 中国现代药物应用, 2020, 14(13): 186-187. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202013086.htm YU X X. To study the effect of docetaxel monotherapy in the treatment of elderly patients with advanced non-small cell lung cancer[J]. Chinese Journal of Modern Drug Application, 2020, 14(13): 186-187. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202013086.htm
[3]	李琳琳, 项保利, 薛乾隆, 等. 吉西他滨对非小细胞肺癌患者化疗疗效与其病理组织基因表达的相关性[J]. 中国临床药理学杂志, 2018, 34(7): 793-795, 799. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201807017.htm LI L L, XIANG B L, XUE Q L, et al. Chemotherapeutic effect of gemcitabine for non-small cell lung cancer patients and the correlation with the expression of gene in pathological tissue[J]. The Chinese Journal of Clinical Pharmacology, 2018, 34(7): 793-795, 799. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201807017.htm
[4]	徐家亮, 徐春华, 姜美慧, 等. 精确放疗联合吉非替尼治疗老年EGFR突变阳性局部晚期非小细胞肺癌的疗效[J]. 中国现代药物应用, 2020, 14(20): 117-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202020055.htm XU J L, XU C H, JIANG M H, et al. Efficacy of precision radiotherapy combined with gefitinib in the treatment of elderly patients with EGFR mutation-positive locally advanced non-small cell lung cancer[J]. Chinese Journal of Modern Drug Application, 2020, 14(20): 117-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWYY202020055.htm
[5]	李琳琳, 项保利, 薛乾隆. 西罗莫司对肺癌细胞增殖及哺乳动物西罗莫司靶蛋白信号通路相关蛋白表达的影响[J]. 中国临床药理学杂志, 2018, 34(14): 1645-1648. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201814017.htm LI L L, XIANG B L, XUE Q L, et al. Effect of rapamycin on the proliferation of lung carcinoma cell and the expression of mammalian target of rapamycin signal path related protein[J]. The Chinese Journal of Clinical Pharmacology, 2018, 34(14): 1645-1648. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201814017.htm
[6]	陆小芳, 周晓荣, 钱东林, 等. 吉西他滨注射液联合顺铂注射液治疗中晚期非小细胞肺癌患者的临床研究[J]. 中国临床药理学杂志, 2021, 37(7): 805-808. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202107004.htm LU X F, ZHOU X R, QIAN D L, et al. Clinical trial of gemcitabine injection combined with cisplatin injection in the treatment of patients with advanced non-small cell lung cancer[J]. The Chinese Journal of Clinical Pharmacology, 2021, 37(7): 805-808. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202107004.htm
[7]	National Institutes of Health (NIH).Cancer stat facts: lung and bronchus cancer[EB/OL].[2019-06-02].http://seer.cancer.gov/statfacts/html/lungb.html.
[8]	张坦, 王艺曈, 方翼. 非小细胞肺癌靶向治疗药物的研究现状[J]. 中国临床药理学杂志, 2017, 33(11): 1054-1057. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201711029.htm ZHANG T, WANG Y T, FANG Y. Research status of targeted agents for the treatment of non-small cell lung cancer[J]. The Chinese Journal of Clinical Pharmacology, 2017, 33(11): 1054-1057. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201711029.htm
[9]	何碧珊. 中国老年晚期非小细胞肺癌患者使用奥希替尼不良反应分析[J]. 临床合理用药杂志, 2020, 13(19): 12-15. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202019005.htm HE B S. Analysis of adverse reactions of osimertinib among elderly patients with advanced non-small cell lung cancer in China[J]. Chinese Journal of Clinical Rational Drug Use, 2020, 13(19): 12-15. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202019005.htm
[10]	康乐, 苗晋鑫, 方晓艳, 等. 基于网络药理学及分子对接的通关藤治疗非小细胞肺癌的现代机制[J]. 重庆理工大学学报(自然科学), 2021, 35(7): 191-200. https://www.cnki.com.cn/Article/CJFDTOTAL-CGGL202107024.htm KANG L, MIAO J X, FANG X Y, et al. Modern mechanism of marsdenia tenacissima in the treatment of non-small cell lung cancer based on network pharmacology and molecular docking[J]. Journal of Chongqing University of Technology: Natural Science, 2021, 35(7): 191-200. https://www.cnki.com.cn/Article/CJFDTOTAL-CGGL202107024.htm
[11]	张梦迪, 牟睿宇, 刘宏根, 等. 消癌平注射液联合化疗治疗晚期非小细胞肺癌的Meta分析[J]. 天津中医药, 2019, 36(5): 466-473. https://www.cnki.com.cn/Article/CJFDTOTAL-TJZY201905014.htm ZHANG M D, MOU R Y, LIU H G, et al. Meta-analysis of Xiaoaiping Injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Tianjin Journal of Traditional Chinese Medicine, 2019, 36(5): 466-473. https://www.cnki.com.cn/Article/CJFDTOTAL-TJZY201905014.htm
[12]	胡晓琳, 刘喜松, 陈细定. 消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌的临床评价[J]. 药物评价研究, 2017, 40(2): 266-269. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ201702027.htm HU X L, LIU X S, CHEN X D. Clinical effect of Xiaoaiping Injection combined with gemcitabine and carboplatin in treatment of ⅢB and Ⅳ non-small cell lung cancer[J]. Drug Evaluation Research, 2017, 40(2): 266-269. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ201702027.htm
[13]	姜婷婷, 张梦培, 王志恒, 等. 基于现代文献比较分析老年晚期非小细胞肺癌临床试验疗效终点指标[J]. 世界中西医结合杂志, 2020, 15(5): 841-844, 849. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202005014.htm JIANG T T, ZHANG M P, WANG Z H, et al. Comparative analysis of efficacy endpoints in clinical trials of elderly patients with advanced non-small cell lung cancer[J]. World Journal of Integrated Traditional and Western Medicine, 2020, 15(5): 841-844, 849. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202005014.htm
[14]	林洪生. 恶性肿瘤中医诊疗指南[M]. 北京: 人民卫生出版社, 2014: 242-267. LIN H S. Guidelines for traditional Chinese medicine diagnosis and treatment of malignant tumors[M]. Beijing: People's Medical Press, 2014: 242-267.
[15]	MAZIERES J, KOWALSKI D, LUFT A, et al. Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(3): 271-280.
[16]	WANG P L, YANG J, ZHU Z F, et al. Marsdenia tenacissima: a review of traditional uses, phytochemistry and pharmacology[J]. Am J Chin Med, 2018. DOI: 10.1142/S0192415X18500751.
[17]	CHEN J J, ZHANG X Q, XIAO X, et al. Xiao-Ai-Ping injection enhances effect of paclitaxel to suppress breast cancer proliferation and metastasis via activating transcription factor 3[J]. Integr Cancer Ther, 2020, 19: 1534735420906463. DOI: 10.1177/1534735420906463.
[18]	朱丽娜, 武文辉, 钟敏, 等. 消癌平联合吉非替尼对进展期非小细胞肺癌患者凝血功能及临床疗效的影响[J]. 实用癌症杂志, 2020, 35(1): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202001021.htm ZHU L N, WU W H, ZHONG M, et al. Clinical effect of XiaoAiPing Injection combined with gefitinib on blood coagulation state of advanced NSCLC patients[J]. The Practical Journal of Cancer, 2020, 35(1): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-SYAZ202001021.htm
[19]	段桦, 胡凯文, 崔慧娟, 等. 108例老年晚期非小细胞肺癌患者预后因素分析[J]. 癌症进展, 2020, 18(5): 470-474. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202005011.htm DUAN H, HU K W, CUI H J, et al. Multivariate analysis of prognostic factors in the elderly patients with advanced non-small cell lung cancer: a study of 108 patients[J]. Oncology Progress, 2020, 18(5): 470-474. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202005011.htm
[20]	张添威, 陈卫建, 张蓉映, 等. 基于"痰毒"理论探讨化痰解毒法对中晚期非小细胞肺癌患者带瘤生存的临床意义[J]. 中华全科医学, 2019, 17(12): 2042-2045, 2150. doi: 10.16766/j.cnki.issn.1674-4152.001123 ZHANG T W, CHEN W J, ZHANG R Y, et al. Clinical significance of phlegm detoxification on survival with tumor in advanced NSCLC patients based on the phlegm-poison theory[J]. Chinese Journal of General Practice, 2019, 17(12): 2042-2045, 2150. doi: 10.16766/j.cnki.issn.1674-4152.001123
[21]	苏连华. 祛瘀泻肺汤治疗痰湿壅肺兼血瘀型COPD急性加重期临床疗效[J]. 中国误诊学杂志, 2021, 16(2): 111-113. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWZX202102006.htm SU L H. Analysis of clinical effect of Quyu Xiefei Decoction on acute exacerbation on COPD with phlegm-dampness obstructing lung and blood stasis[J]. Chinese Journal of Misdiagnostics, 2021, 16(2): 111-113. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWZX202102006.htm
[22]	DAL BELLO M G, FILIBERTI R A, ALAMA A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients[J]. J Transl Med, 2019, 17(1): 74.
[23]	胡彦辉, 崔庆丽, 马东阳, 等. 消癌平注射液对非小细胞肺癌患者T淋巴细胞亚群的影响[J]. 中国临床医生杂志, 2019, 47(5): 570-573. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS201905025.htm HU Y H, CUI Q L, MA D Y, et al. Effect of Xiaoaiping injection on T lymphocyte subsets in patients with non-small cell lung cancer[J]. Chinese Journal for Clinicians, 2019, 47(5): 570-573. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS201905025.htm
[24]	王祁民, 孙利民, 许剑峰. 通关藤及其制剂消癌平抗肿瘤的相关性研究[J]. 临床误诊误治, 2017, 30(12): 102-105. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ201712039.htm WANG Q M, SUN L M, XU J F. Correlation study of MTE and its preparation Xiaoaiping against tumor[J]. Clinical Misdiagnosis & Mistherapy, 2017, 30(12): 102-105. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ201712039.htm